TRIAL DETAIL

Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer

Drug:
Trial Name:
Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 10/01/2011
Age of Trial (yrs) 12
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor + MEK inhibitor
Strategy:
Block KIT + Block related tumor signal paths
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
J1162, NA_00048646
Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Patient Contact:
Kathy Elza-Brown, RN 410-502-5140 kelzabr1@jhmi.edu Nilo Azad, MD 410-614-9169 nazad2@jhmi.edu
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
Official Title: Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
Baltimore
MD
21231
USA
1505 Holcombe Blvd.
Houston
TX
77030
USA